A Phase 1b Study to Evaluate the Safety and Tolerability of Andecaliximab (GS-5745) as Monotherapy and in Combination With Anti-Cancer Agents in Japanese Subjects With Gastric or Gastroesophageal Junction Adenocarcinoma
Phase of Trial: Phase I
Latest Information Update: 15 Dec 2017
At a glance
- Drugs Andecaliximab (Primary)
- Indications Gastric cancer
- Focus Adverse reactions
- Sponsors Gilead Sciences
- 12 Dec 2017 Planned End Date changed from 1 May 2019 to 1 Nov 2018.
- 12 Dec 2017 Planned primary completion date changed from 1 May 2019 to 1 Nov 2018.
- 10 Nov 2017 Status changed from active, no longer recruiting to recruiting.